Morysa (Memantine Hydrochloride)

Memantine is a non‑competitive antagonist of the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor‑associated ion channel at a site distinct from the glutamate binding site, it blocks excessive calcium influx that occurs during pathological glutamate stimulation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission.

The specific dose of Morysa is determined by the prescribing clinician based on the patient’s clinical status, renal function, and tolerance. Typical titration starts with a low dose that is gradually increased to the target maintenance dose, but the exact regimen must be individualized and documented in the prescription.

The safety of memantine hydrochloride in pregnancy and lactation has not been established. Animal studies have not shown clear teratogenic effects, but human data are limited. Therefore, Morysa should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the prescriber should discuss alternatives.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Morysa. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details, and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine, and galantamine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe disease and may be combined with an acetylcholinesterase inhibitor for additive benefit. Its side‑effect profile differs, with fewer gastrointestinal effects but a higher incidence of dizziness and confusion.

Morysa should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture, light, and humidity. Keep the product out of reach of children and do not store it in bathrooms or near heat sources. Do not use the medication after the expiration date printed on the label.

Morysa is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not crushed, chewed, or split unless specifically advised. Consistent daily intake at the same time helps maintain stable plasma concentrations and optimizes therapeutic effect.

Although generally well tolerated, Morysa can cause serious adverse events such as seizures, severe allergic reactions (including Stevens‑Johnson syndrome), hepatic dysfunction, and cardiovascular events like hypertension or arrhythmia. Patients should be monitored for new or worsening neurological, dermatological, or cardiac symptoms, and any serious reaction should prompt immediate medical evaluation and possible discontinuation.

Morysa is contraindicated in patients with known hypersensitivity to memantine or any component of the formulation. It should be used with caution, or avoided, in individuals with severe renal impairment, uncontrolled hypertension, a history of seizures, or those receiving other NMDA antagonists. Pregnant or breastfeeding women should only use it when clearly indicated, and pediatric use is not established.